2-戊基噻唑烷 | 41204-65-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 中文名称: 2-戊基噻唑烷
• 英文名称: 2-pentylthiazolidine
• 英文别名: 2-pentyl-thiazolidine；2-Pentylthiazolidin；2-pentyl-1,3-thiazolidine
• CAS: 41204-65-3
• 化学式: C₈H₁₇NS
• 分子量: 159.296
• InChiKey: MOVBGBMWKHJQKI-UHFFFAOYSA-N

物化性质

• 沸点：
  85 °C(Press: 0.7 Torr)
• 密度：
  0.929±0.06 g/cm3(Predicted)
• 保留指数：
  1296

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-戊基噻唑烷 以88%的产率得到
  参考文献：
  名称：

  MEYERS A. I.; DURANDETTA J. L., J. ORG. CHEM. , 1975, 40, NO 14, 2021-2025

  摘要：

  DOI：
• 作为产物：
  描述：

  2-戊基-4,5-二氢-1,3-噻唑 生成 2-戊基噻唑烷
  参考文献：
  名称：

  MEYERS A. I.; DURANDETTA J. L., J. ORG. CHEM. , 1975, 40, NO 14, 2021-2025

  摘要：

  DOI：

文献信息

• THIAZOLIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS
  申请人：Aissaoui Hamed

  公开号：US20100113531A1

  公开（公告）日：2010-05-06

  The invention relates to novel thiazolidine derivatives of the formula (I) wherein A and R 1 are as described in the description and their use as medicaments, especially as orexin receptor antagonists.

  本发明涉及式(I)的新噻唑啉衍生物，其中A和R1如描述中所述，以及它们作为药物的使用，尤其是作为食欲素受体拮抗剂的使用。
• [EN] INGENOL ANALOGS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF<br/>[FR] ANALOGUES D'IGÉNOL, COMPOSITIONS PHARMACEUTIQUES ET MÉTHODES D'UTILISATION DE CES DERNIERS
  申请人：GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO 2) LTD

  公开号：WO2017130156A1

  公开（公告）日：2017-08-03

  The invention relates to compounds of Formula (I), (II), (III) or (IV), salts thereof, pharmaceutical compositions thereof, as well as methods of treating, curing or preventing HIV in subjects.

  该发明涉及Formula (I)、(II)、(III)或(IV)的化合物，其盐，以及治疗、治愈或预防HIV的方法。
• [EN] THIAZOLIDINONE AMIDES, THIAZOLIDINE CARBOXYLIC ACID AMIDES, METHODS OF MAKING, AND USES THEREOF<br/>[FR] AMIDES DE THIAZOLIDINONE, AMIDES D'ACIDE CARBOXYLIQUE DE THIAZOLIDINE, PROCEDES DE FABRICATION ET UTILISATIONS CORRESPONDANTS
  申请人：UNIV TENNESSEE RES FOUNDATION

  公开号：WO2005049591A1

  公开（公告）日：2005-06-02

  Substituted thiazolidinone carboxylic acid amides and substituted thiazolidine carboxylic acid amides according to formulae (I) and (II) are disclosed where the various substituent groups are as defined in the specification. Methods of making these compounds, pharmaceutical compositions containing the compounds, and their use, particularly for treating or preventing cancer, are also disclosed.

  根据公式(I)和(II)披露了替代噻唑烷酮羧酸酰胺和替代噻唑烷羧酸酰胺，其中各种取代基如规范中所定义。还披露了制备这些化合物的方法，含有这些化合物的药物组合物，以及它们的用途，特别是用于治疗或预防癌症。
• [EN] PROCESS FOR OBTAINING MIXTURES OF 4-CARBOXY-1,3-THIAZOLIDINIUM CARBOXYLATE AND N-ACYL-1,3-THIAZOLIDIN-4-CARBOXYLIC ACID<br/>[FR] PROCÉDÉ D'OBTENTION DE MÉLANGES DE CARBOXYLATE DE 4-CARBOXY-1,3-THIAZOLIDINIUM ET D'ACIDE N-ACYL-1,3-THIAZOLIDIN-4-CARBOXYLIQUE
  申请人：UNIV LLEIDA

  公开号：WO2009065797A1

  公开（公告）日：2009-05-28

  The present invention relates to a process for obtaining in a single synthesis stage mixtures of 4-carboxy-1,3-thiazolidium carboxylate and N-acyl-1, 3-thiazolidin-4- carboxylic acids from 1,3-thiazolidin-4-carboxylic acids and derivatives of carboxylic acids, which has the following advantages: use of environmentally friendly solvents, lower energy consumption, lower consumption of acylating reagents, which allows the corresponding mixtures to be obtained with suitable characteristics and specifications, ease of recovery from the reaction medium and high yields.

  本发明涉及一种从1,3-噻唑烷-4-羧酸和羧酸衍生物中在单个合成阶段获得4-羧基-1,3-噻唑烷基羧酸酯和N-酰基-1,3-噻唑烷-4-羧酸混合物的过程，具有以下优点：使用环保溶剂、能源消耗较低、酰化试剂消耗较低，从而允许获得具有适当特性和规格的相应混合物，易于从反应介质中回收并且产率高。
• [EN] METHODS OF QUANTIFYING METHYLGLYOXAL-INDUCED NUCLEIC ACID ADDUCTS<br/>[FR] PROCÉDÉS DE QUANTIFICATION D'ADDUITS À L'ACIDE NUCLÉIQUE INDUITS PAR LE MÉTHYLGLYOXAL
  申请人：HOPE CITY

  公开号：WO2019152728A1

  公开（公告）日：2019-08-08

  Methods of quantifying a N 2 -(1-carboxyethyl)-2'-deoxyguanosine (CEdG) and N 2 -(1-carboxyethyl)-guanosine (CEG) levels in biological samples and comparing those levels to known normal levels can diagnose a number of metabolic disorders or complications associated therewith, including diabetes, its associated complications, and cancer. Methods can also determine whether therapies for disorders are effective by measuring CEdG and CEG levels before and after treatment. Measurement of CEdG and CEG levels is achieved by using liquid chromatography electrospray ionization tandem mass spectrometry.

  测量生物样本中N2-(1-羧基乙基)-2'-脱氧鸟苷（CEdG）和N2-(1-羧基乙基)-鸟苷（CEG）水平的方法，并将这些水平与已知的正常水平进行比较，可以诊断出许多代谢性疾病或相关并发症，包括糖尿病、其相关并发症和癌症。该方法还可以通过在治疗前后测量CEdG和CEG水平来确定治疗疾病的疗效。使用液相色谱电喷雾离子化串联质谱技术可实现CEdG和CEG水平的测量。

表征谱图